Rituxan (Rituximab): Side Effects, Infusion Time, and a Guide to Its Remarkably Wide Range of Uses

Few medications in modern medicine treat as many different conditions as rituximab. Originally developed as a cancer therapy for non-Hodgkin lymphoma, Rituxan has since earned FDA approvals for rheumatoid arthritis, ANCA-associated vasculitis, pemphigus vulgaris, and more — while being used off-label for dozens of additional autoimmune and neurological disorders. Understanding how this versatile B-cell depleting therapy works, what side effects to watch for, and what the infusion experience involves can help patients feel prepared.

How Rituxan Works: B-Cell Depletion Explained

Rituxan is a monoclonal antibody — a lab-made protein designed to target a specific molecule in the body. In this case, it targets CD20, a protein found on the surface of a type of white blood cell called B lymphocytes (B cells).

When rituximab attaches to CD20, it essentially flags those B cells for destruction by the rest of the immune system. Within a few weeks of treatment, the circulating B-cell population drops dramatically. This matters because, depending on the disease being treated, B cells may be producing harmful antibodies, triggering inflammation, or directly promoting tumor growth.

After treatment, B cells gradually repopulate over 6 to 12 months, though the timeline varies from person to person. This is why rituximab infusions are typically given in cycles spaced several months apart rather than continuously.

FDA-Approved Uses

Rituxan holds FDA approval for an unusually broad range of conditions:

• Non-Hodgkin lymphoma (NHL) — the original indication; used alone or in combination with chemotherapy
• Chronic lymphocytic leukemia (CLL) — in combination with other agents
• Rheumatoid arthritis (RA) — for moderate to severe RA that has not responded adequately to TNF inhibitors
• Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) — collectively known as ANCA-associated vasculitis
• Pemphigus vulgaris — a serious autoimmune blistering skin disease

Common Off-Label Uses

Beyond its approved indications, rituximab is prescribed off-label for a strikingly long list of conditions where B cells play a pathological role. Some of the most common include:

• Neuromyelitis optica spectrum disorder (NMOSD) — widely used as a first-line therapy despite being off-label
• Myasthenia gravis (MG) — particularly in patients who are anti-MuSK antibody positive
• Multiple sclerosis (MS) — used off-label before Ocrevus (a related anti-CD20 antibody) was approved; still prescribed in some cases due to cost differences
• Immune thrombocytopenic purpura (ITP)
• Autoimmune hemolytic anemia
• Membranous nephropathy
• Lupus nephritis

The off-label use of rituximab is so widespread that many specialists consider it a standard treatment for conditions where it lacks a formal FDA indication. Insurance coverage for off-label uses can be more challenging to secure, however, so patients should be prepared for potential insurance hurdles.

Infusion Time: First vs. Subsequent Doses

One of the most common questions about Rituxan is how long the infusion takes. The answer depends heavily on whether it is the first or a subsequent infusion.

The first infusion is intentionally slow because infusion reactions are most common during the initial exposure. Once a patient demonstrates they can tolerate rituximab, later infusions can often be given more quickly. Some cancer centers and infusion centers offer a 90-minute rapid infusion protocol for eligible patients, which can make a significant quality-of-life difference.

Premedication and Infusion Reactions

Before each rituximab infusion, patients receive premedications to reduce the risk of infusion reactions. A standard premedication regimen includes:

• Acetaminophen (Tylenol) — for fever and body aches
• Diphenhydramine (Benadryl) — an antihistamine to prevent allergic-type reactions
• Methylprednisolone or another corticosteroid — to reduce inflammation (sometimes given IV)

Even with premedication, infusion reactions occur in up to 77% of patients during the first infusion for oncology indications, though most are mild (Grade 1-2). Symptoms can include fever, chills, rigors, nausea, itching, swelling, and drops in blood pressure. The infusion nurse will slow or temporarily stop the infusion if a reaction occurs, then resume at a lower rate once symptoms resolve.

Side Effects: Common and Serious

Common Side Effects

• Infusion-related reactions (fever, chills, nausea)
• Infections (upper respiratory, urinary tract)
• Fatigue
• Headache
• Muscle spasms
• Neutropenia (low white blood cell count), often delayed

Serious Side Effects

• Severe infusion reactions — rarely including anaphylaxis
• Serious infections — due to B-cell depletion, including reactivation of hepatitis B (screening is required before starting treatment)
• Progressive multifocal leukoencephalopathy (PML) — extremely rare but possible, similar to Tysabri
• Tumor lysis syndrome — relevant mainly in cancer patients with high tumor burden
• Cardiac arrhythmias — monitoring is recommended for patients with pre-existing heart conditions

Long-Term Risks: Infections and Low Immunoglobulins

For patients receiving rituximab over multiple years — common in chronic autoimmune conditions — one of the most important long-term concerns is hypogammaglobulinemia, meaning abnormally low levels of immunoglobulin (antibody) proteins in the blood.

Repeated B-cell depletion can gradually reduce the body’s ability to produce new antibodies. Studies suggest that up to 20-40% of patients on long-term rituximab develop low IgG levels, which increases susceptibility to infections — particularly sinopulmonary infections (sinusitis, bronchitis, pneumonia).

Rituxan Biosimilars: Truxima and Others

As Rituxan’s patent protections have expired, several biosimilar versions have entered the market. A biosimilar is essentially a near-identical copy of a biologic drug that has been proven to have no clinically meaningful differences from the original.

Truxima (rituximab-abbs) was the first rituximab biosimilar approved in the United States. Others include Ruxience (rituximab-pvvr) and Riabni (rituximab-arrx). These biosimilars are approved for the same indications as Rituxan and offer meaningful cost savings — often 15-30% less than brand-name Rituxan.

Patients sometimes worry about being switched from Rituxan to a biosimilar by their insurance plan. The clinical evidence is reassuring: biosimilars undergo rigorous FDA review, and post-market surveillance has not identified significant safety or efficacy differences. However, patients should always be informed when a switch occurs and can discuss any concerns with their prescriber.

Home Infusion Considerations

After demonstrating tolerance during initial infusions at a clinic, some patients may qualify for Rituxan home infusion. This option can be especially appealing given the lengthy infusion times and the need for repeat cycles over years.

Home infusion for rituximab requires a trained infusion nurse, appropriate premedication, and emergency supplies on hand. The first infusion is almost always conducted in a clinical setting, and most providers require at least one or two uneventful clinic infusions before approving the home setting.

For patients comparing rituximab with its newer relative ocrelizumab, see the Rituxan vs. Ocrevus comparison and the Ocrevus drug guide.